Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sm29 and Meglumine Antimoniate in Cutaneous Leishmaniasis
NCT06000514Phase 2Completed
- Sponsor
- Hospital Universitário Professor Edgard Santos
- Start
- Jan 2019
- Primary completion
- Apr 2022
- Countries
- 1
01
Overview
Phase 2, randomised trial in cutaneous leishmaniasis (CL) (2 arms), sponsored by Hospital Universitário Professor Edgard Santos. Primary endpoint: Cure at 90 days. Started Jan 2019; status: completed.
02
Conditions
cutaneous leishmaniasis (CL)
Beyond the preview
Go deeper on NCT06000514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06000514.